Skip to main content

MetasTx, LLC

  • | Biotech or pharma, therapeutic R&D
  • | Diagnostics
MetasTx, LLC

MetasTx is working to block metastases of cancer cells from solid tumors including prostate, breast and skin by early detection and blockade of mesenchymal-to-epithelial transition (EMT). Creating novel drug focused on inhibiting P21-activated kinase (PAK 1) and companion diagnostic to detect activation of EMT. Initial target - 2 million men on active surveillance for prostate cancer.

Market Opportunity

$11.5 billion US drug market,

Mortality rates unchanged over the past 2 decades despite 35 drugs available.

Platform focus – Inhibit EMT

Target PAK1 to create First-In-Class drug to inhibit metastases.

Personalized and aggressive treatment intervention when needed.

Avoid unnecessary prostatectomies.

MetasTx Strengths:

1.    Science Foundation – 35 published articles

2.    Demonstrated capabilities for AI Drug and Biomarker Discovery

3.    Efficient business strategy / Laser focus on exit by Acquisition

4.    Extraordinary Leadership Team

Seeking lead for preferred equity Round of $2.5 M.

Address

Pittsburgh
Pennsylvania
United States
Visit website

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors